Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers

Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers
复制标题

DOI:
10.1128/jvi.01005-09
复制
发表时间:
2009-11-15
影响因子:
5.4
通讯作者:
Cohen, Jeffrey I.
Cohen, Jeffrey I.
中科院分区:
医学2区
文献类型:
--
作者:
Hoshino, Yo;Katano, Harutaka;Cohen, Jeffrey I.

文献摘要

被引文献

相似文献

EB病毒(EBV)在血液中的B细胞中建立潜伏感染,并且健康个体中的潜伏EBV负荷通常随时间稳定,维持“设定点”。“目前尚不清楚健康个体长期抗病毒治疗后EBV载量是否发生变化。我们用伐昔洛韦或不抗病毒治疗志愿者1年,每3个月用一种新的、高灵敏度的检测方法测量B细胞中EBV DNA的量。在接受伐昔洛韦的受试者中,EBV感染的B细胞数量减少(半衰期为11个月; P = 0.02),但在对照组中没有减少(半衰期为31年; P = 0.86)。伐昔洛韦组与对照组的EBV感染的B细胞数量随时间变化的直线斜率差异接近显著性(P = 0.054)。相反,两组中每个B细胞的EBV DNA拷贝数保持不变(对照组和伐昔洛韦组分别为P = 0.62和P = 0.92)。伐昔洛韦在长期给药时可降低EBV感染的B细胞的频率,并且理论上,如果不发生再感染,则可将EBV从体内根除。
Epstein-Barr virus (EBV) establishes a latent infection in B cells in the blood, and the latent EBV load in healthy individuals is generally stable over time, maintaining a "set point." It is unknown if the EBV load changes after long-term antiviral therapy in healthy individuals. We treated volunteers with either valacyclovir (valaciclovir) or no antiviral therapy for 1 year and measured the amount of EBV DNA in B cells every 3 months with a novel, highly sensitive assay. The number of EBV-infected B cells decreased in subjects receiving valacyclovir (half-life of 11 months; P = 0.02) but not in controls (half-life of 31 years; P = 0.86). The difference in the slopes of the lines for the number of EBV-infected B cells over time for the valacyclovir group versus the control group approached significance (P = 0.054). In contrast, the number of EBV DNA copies per B cell remained unchanged in both groups (P = 0.62 and P = 0.92 for the control and valacyclovir groups, respectively). Valacyclovir reduces the frequency of EBV-infected B cells when administered over a long period and, in theory, might allow eradication of EBV from the body if reinfection does not occur.